WEST LAFAYETTE, Ind., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, president and CEO of Endocyte, will be presenting at two upcoming investor conferences:
-
The 2011 William Blair Life Sciences Conference on Wednesday, Sept. 7, at 11:30 a.m. EDT in New York
- The Baird 2011 Health Care Conference on Thursday, Sept. 8, at 9:30 a.m. EDT in New York
A separate audio webcast link for each conference will be available on the Company's website under "Events & Presentations" in the Investor Relations section at www.endocyte.com. The webcasts will be archived shortly after the live events and a replay will be available on the Company's website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.